Physician profile
Max A Bulmash
NPI 1215902242
$339.91
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.81 · 2022: $104 · 2023: $189 · 2024: $33.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $125.00 | 2023 | Dexcom G7 Gss (161) |
| Ge Healthcare | $104.18 | 2022 | |
| Merck Sharp & Dohme LLC | $28.68 | 2019-2023 | Rotateq, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $24.94 | 2023 | |
| Sanofi Pasteur INC. | $23.73 | 2023 | |
| Phadia US INC. | $17.11 | 2024 | Immunocap |
| Abbvie INC. | $16.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Bulmash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.